Hospitals Histogenics and FDA Continue to Discuss NeoCart® Phase 3 Clinical Trial Data and Potential Regulatory Pathway byJosh SandbergNovember 29, 2018
Biologics Hospitals Histogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway byJosh SandbergNovember 1, 2018
Hospitals Histogenics to Meet With FDA to Discuss NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway byJosh SandbergSeptember 27, 2018
Biologics Histogenics Announces Top-Line Results From Phase 3 Clinical Trial of NeoCart® in Patients With Knee Cartilage Damage byJosh SandbergSeptember 6, 2018
Biologics Top Stories Histogenics Corporation and MEDINET Co., Ltd Enter Into Licensing Agreement for Development and Commercialization of NeoCart for the Japanese Market byJosh SandbergDecember 22, 2017
Biologics Hospitals Histogenics Agreement With Japan Pharmaceuticals and Medical Devices Agency and Regulatory Pathway for NeoCart® byJosh SandbergMay 8, 2017
Sports Medicine Histogenics Announces Publication of MRI Data From NeoCart® Phase 1 and Phase 2 Clinical Trials in the American Journal of Sports Medicine byJosh SandbergJanuary 16, 2017
Financial Histogenics Corporation Acquires NeoCart® Development and Commercialization Rights for Japanese Market byJosh SandbergMay 11, 2016
Hospitals Histogenics Corporation Announces Amendment to NeoCart® Phase 3 Clinical Trial Enrollment Criteria byJosh SandbergDecember 22, 2015
Biologics Extremities Histogenics Corporation and Collagen Solutions plc Establish Supply Agreement byJosh SandbergSeptember 16, 2015
